Selpercatinib

Selpercatinib is a tyrosine kinase inhibitor indicated for the treatment of certain types of cancers, particularly those harboring specific genetic alterations.

Indications

-Treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) -Treatment of advanced or metastatic RET-mutant medullary thyroid cancer (MTC) -Treatment of advanced or metastatic RET fusion-positive thyroid cancer

Dosage

The recommended dosage varies depending on the specific indication and patient's weight. Typically administered orally once daily.

Contra-Indications

Hypersensitivity to selpercatinib or any component of the formulation

Special Precautions

-Risk of hypertension -Risk of hepatotoxicity -Risk of QT interval prolongation -Monitor for signs and symptoms of interstitial lung disease/pneumonitis

Side Effects

Common side effects may include: -Hypertension -Fatigue -Diarrhea -Muscle and joint pain -Increased liver enzymes -Decreased white blood cell count

Drug Interactions

-Strong CYP3A inhibitors and inducers may affect selpercatinib plasma concentrations. -Avoid concomitant use with drugs known to prolong the QT interval or cause Torsades de Pointes.